Key facts
- This page summarizes Michael S. Lee's Form 4 filing for IGM Biosciences, Inc. (IGMS).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 14 Aug 2025, 19:35.
Michael S. Lee - 14 Aug 2025 Form 4 Insider Report for IGM Biosciences, Inc. (IGMS)
- Reporting relationship
- Director
- Issuer ticker
- IGMS
- Reported as of
- 14 Aug 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 14 Aug 2025, 19:35:42 UTC
- Prior SEC filing
- 16 Jul 2025
- Next SEC filing
- 15 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael Lee
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Michael S. Lee filed Form 4 for IGM Biosciences, Inc. (IGMS) on 14 Aug 2025.
Change
- Previous filing in this sequence was filed on 16 Jul 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001748010
Primary reporting owner
Lee Michael Stewart
- Relationship
- Director
- Address
- C/O REDMILE GROUP, LLC, ONE LETTERMAN DR., BLDG. D, SUITE D3-300, SAN FRANCISCO
- Signature
- /s/ Michael Lee
- Signature date
- 14 Aug 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
IGMS
transaction
Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -12,712
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 14 Aug 2025
- Ownership
- Direct
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Michael S. Lee is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 3 footnotes
Footnote F1
On August 14, 2025, pursuant to the terms of the Agreement and Plan of Merger, dated as of July 1, 2025, among the Issuer, Concentra Biosciences, LLC, a Delaware limited liability company ("Parent"), and Concentra Merger Sub V, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub completed a tender offer to purchase all outstanding shares of the Issuer's Common Stock and Non-Voting Common Stock in exchange for (a) a price per share of $1.247 in cash (the "Offer Price"), subject to applicable tax withholding and without interest, plus (b) one contingent value right ("CVR") per share subject to the terms and conditions of a Contingent Value Rights Agreement . The tender offer expired one minute following 11:59 p.m., Eastern Time, on August 13, 2025 (the "Offer Closing").
Footnote F2
The reported securities were granted to Michael Lee, a managing director of Redmile Group, LLC ("Redmile"), in connection with his service as a member of the Board of Directors of the Issuer. Pursuant to the policies of Redmile, Mr. Lee held these securities as a nominee on behalf, and for the sole benefit, of Redmile and assigned all economic, pecuniary and voting rights in respect of the securities to Redmile. Mr. Lee disclaimed beneficial ownership of the reported securities, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee was the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Footnote F3
The securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the securities except to the extent of their pecuniary interest therein, if any, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
SEC remarks
Mr. Lee, a managing director of Redmile, resigned as a member of the board of directors of the Issuer immediately prior to the effective date and time of the merger between Issuer and Merger Sub.